The Inflation Reduction Act - A Market-Driven Event Impacting the Development of New Treatments

The IRA is market-driven. It is changing the US healthcare landscape with new approaches toward drug pricing, health plan redesign (Medicare Part D, potential impact on commercial benefit design, plan sponsors, and manufacturers), and the impact on R&D investment, especially our approach to pipeline and BD deals all impacting future patient care and innovation.

What can we be considering to address these challenges and get ahead of disease together?